GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2008

Luminex and BD Ally to Develop Tests for Cancer Prediction

  • Luminex and BD are joining forces to develop molecular diagnostics for certain cancers. BD Diagnostics-TriPath will develop, market, and sell these tests using Luminex’ multiplexing xMAP® Technology platform.

    BD develops technologies for cervical cancer screening as well as diagnostic products for the detection of cancer. The aim is to expand its offerings to include tests for solid tumor cancers using Luminex' platform.

    The xMAP Technology is a multiplexing platform that allows scientists to conduct multiple, simultaneous tests on one patient sample. “We believe providing biomarker testing in a multiplex format would allow detection of cancer at an earlier stage,” says Wayne Brinster, vp and GM of BD Diagnostics-TriPath.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?